Introduction
Tissue factor is the main initiator of the blood coagulation cascades. Expression of this protein is restricted to subendothelial tissues, and the peripheral blood cells and endothelial cells of healthy individuals are negative for TF. 1 Monocytes, however, are the only blood cells that can be induced to express this protein. 2 In septic conditions TF expression in monocytes is known to play a major role in development of disseminated intravascular coagulation (DIC). 3 Moreover, pathological expression of TF on leukaemic cells seems to be an important finding for thrombotic complications. 4 Acute promyelocytic leukaemia (APL) is the most common myeloid leukaemia associated with thrombotic complications, ultimately leading to DIC. 5 APL is a subtype of acute myelogenous leukaemia with the characteristic chromosome translocation that disrupts the retinoic acid receptor (RAR)-␣ gene on chromosome 17 and fuses it to the promyelocytic leukaemia (PML) gene at chromosome 15, thus resulting in the PML/RAR␣ fusion protein. Beyond pathological expression, TF is also expressed on the surface of bone marrow derived myeloid progenitor cells. 6 The role of the protein during myeloid maturation is however still poorly understood. Thus, understanding the mechanisms of the specific regulation of TF in different cells of myeloid origin is of great importance for interventions aiming at alleviating the thrombotic complications.
Retinoic acid induces differentiation and growth arrest in myeloid precursor cells and in leukaemic cells. 7, 8 This differentiation process has been shown to be accompanied by suppression of TF expression in various myeloid leukaemia cells. [9] [10] [11] RA therapy is also widely used in treatment of APL patients, giving a remission rate over 90%. 12 Nevertheless, there is a limited knowledge about the mechanisms underlying the processes of RA-induced TF suppression in APL and other myeloid leukaemic cells. It is known that RA acts through nuclear steroid receptors: retinoic acid receptors (RAR␣, ␤, ␥) and retinoid X receptors (RXR␣, ␤, ␥). RA treatment of various cells induces formation of RAR-RXR transcriptional complexes on the RA response element (RARE) in promoters of RA-regulated genes. Although RXR has been considered as a silent transcriptional partner, 13 the activation of both RXR and RAR is essential for full transcriptional activity and induction of differentiation in myeloid cells. 14, 15 The abnormal PML/RAR␣ gene in APL cells results in defective RA signalling and is responsible for the leukaemic phenotype of these cells. 16 It was shown that in NB4 cells the activation of RAR␣ or RAR␤ is sufficient to induce TF down-regulation. 17, 18 However, the abnormal retinoic acid signalling by the PML/RAR␣ nuclear oncoprotein in NB4 cells does not allow us to expand these data on TF regulation in other myeloid and leukaemic cells.
In this report, we have used RA nuclear-receptor-specific ligands to reveal the mechanisms of retinoid-induced TF suppression in the APL cell line NB4 and in the monoblastic cell line U-937. Although RAR␣ activation can be shown to be sufficient for TF suppression in NB4 cells, we show that in a cell line with a normal RAR␣ gene the full suppression of TF requires activation of both RAR␣ and RXR. Moreover, TF suppression in both of the cell lines was found to be coherent with induction of general myeloid differentiation markers, which might imply that TF suppression and cell differentiation are regulated concomitantly.
Materials and methods

Cells
The NB4 cells, established from a human acute promyelocytic leukaemia (M3) 19 (kindly provided by Inge Olsson, University of Lund, Lund, Sweden), and the human monoblastic cell line U-937 (subline U-937-1), derived from a patient with histocytic lymphoma 20, 21 were maintained in RPMI 1640 medium supplemented with 10% foetal bovine serum (Sigma, St Louis, MO, USA), 1% of L-glutamine, 100 U/ml of penicillin and 50 g/ml of streptomycin (Biochrom, Berlin, Germany). The cells were routinely screened for mycoplasma infection at regular intervals. The cells at a concentration of 2 × 10 5 /ml were induced with different retinoids: all-trans retinoic acid (ATRA; Sigma), TTNPB, SR11237, Ro40-6055, Ro48-2249, Ro44-4753 and Ro41-5253 (Table 1) . Retinoids were dissolved in ethanol to the 1 mM concentration and further dissolved in the culture medium. The final concentration of ethanol in the culture media was less than 0.1%, which was found to have no effect on the TF expression in these cells. During the period of incubation we did not observe any changes in the cell viability (Ͼ90%). Cell culture medium was checked for endo- Table 1 The specificities of the retinoids used in the study toxin contamination with limulus amebocyte lysate assay (Chromogenix AB, Mö lndal, Sweden), and endotoxin concentration was found less than 5 pg/ml at working concentrations of the reagents.
Analysis of TF mRNA
Total RNA was isolated from 2 × 10 6 cells with TRIZOL reagent (Life Technologies, St Louis, MO, USA). RNA concentration was determined at 260 nm with a spectrophotometer (SPECTRAmax 250, Molecular Devices, Sunnyvale, CA, USA), and the integrity of 28S and 18S ribosomal RNA was checked in ethidium bromide-stained agarose gel. Total RNA (1 g) was subjected to a reverse transcription (RT) reaction for 90 min at 37°C in 20 l volume containing 200 U MMLV RT enzyme, 0.5 mM dNTP mixture, 10 mM DTT, 0.25 g oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and 1× first strand buffer (50 mM Tris-HCI, 75 mM KCI, 3 mM MgCl 2 ) (Life Technologies).
The relative amount of reverse transcribed TF mRNA was quantitated with the TaqMan real-time polymerase chain reaction (PCR) assay. The method is based on 5Ј-3Ј nuclease activity of the Taq polymerase, in which the enzyme degrades the dual-labelled fluorogenic target-specific TaqMan probe, resulting in an accumulation of fluorescent emission as the reaction proceeds.
22 Table 2 shows the sequences of PCR primers and fluorescent TaqMan probes for TF and the housekeeping gene ␤-actin. PCR reaction mixture of 25 l contained the TaqMan buffer A (50 mM KCl, 10 mM EDTA, 10 mM Tris-HCl pH 8.3, 60 nM passive reference ROX), 3 mM MgCl 2 , dNTP mixture (0.2 mM of each), 1.25 U AmpliTaq Gold (Perkin Elmer, Foster City, CA, USA), 300 nM forward and reverse primers, 200 mM probe and 1 l of RT reaction product. For each sample two parallel reactions were performedone with TF primers and probe, and the other with ␤-actin Table 2 Primers and probes used for TaqMan real-time PCR primers and probe. The PCR reaction was carried out in ABI PRISM 7700 Sequence Detection System (Perkin Elmer Applied Biosystems) in a two-step protocol: 10 min at 95°C (denaturation of DNA and activation of AmpliTaq Gold) and 50 cycles amplification by 15 s at 95°C and 1 min at 60°C. The real-time detection of amplification signal information was captured by the ABI PRISM 7700 and the appearance of the amplification signal, threshold cycle number (C T ), was registered for each sample. The differences in TF mRNA expression were determined by the comparative C T method as described in ABI PRISM 7700 User Bulletin No. 2. Briefly, the difference in TF and ␤-actin C T values (⌬C T ) was determined and calibrated to the ⌬C T value of the uninduced sample (⌬⌬C T = ⌬C TX − ⌬C T0 ). The relative TF mRNA expression related to uninduced sample is determined by evaluating the expression: 2 −⌬⌬CT .
Flow cytometry
The 
Procoagulant activity
The procoagulant activity of TF was determined in a previously described two-stage amidolytic assay. 23 Briefly, aliquots with 3 × 10 5 cells were washed twice with PBS and placed in the wells of a 96-well microtitre plate. The reaction mixture contained 0.6 mM of the chromogenic substrate, S-2222 (Chromogenix AB), 10 M of ionomycin (Calbiochem, La Jolla, CA, USA) and the coagulation factor concentrate Prothromplex-T TIM 4 (Immuno, Vienna, Austria) at a final concentration of 1 U/ml of FVII and 1.2 U/ml of FX. The reaction was started by adding of 2 mM final concentration of CaCl 2 and the solution was incubated for 30 min at 37°C. The change in absorbance at 405 nm was determined with a spectrophotometer (SPECTRAmax 250, Molecular Devices).
Statistical analysis
Statistical analysis was performed by Student's t-tests for dependent samples and P values less than 0.05 were considered statistically significant.
Results
RAR activation induces suppression of TF in APL (NB4) cells
Retinoid-induced differentiation in myeloid cells is known to require the activation of the RAR-RXR nuclear receptor complex.
14 Therefore, we first studied if the activation of the RAR-RXR complex is also a requirement for retinoid-induced suppression of TF mRNA in the APL cell line NB4. The NB4 cells were treated with the RXR-selective synthetic agonist SR11237 (0.1 M), the RAR-selective agonist TTNPB (0.01 M) or with the combination of the ligands. 24 To achieve maximum specificity we used the lowest effective ligand concentrations. We have found that ATRA-induced TF suppression in NB4 cells is an early event, followed by the other differentiation related changes, 11 and thus retinoid-induced TF changes were measured after 24 h. As shown in Figure 1a the activation of RARs with the selective ligand TTNPB resulted in almost complete (95%, P Ͻ 0.005) down-regulation of TF mRNA levels, whereas induction by combination of RAR and RXR agonists did not give any further suppression. The RXR agonist SR11237 alone induced only partial suppression of TF mRNA.
Consistent with the results obtained from TF mRNA measurements we found a similar suppression of TF antigen levels in NB4 cells (Figure 1b) . After 24-h treatment of NB4 cells with TTNPB the expression of TF antigen was inhibited by 75% (P Ͻ 0.005). No marked effect on TF antigen expression was found when NB4 cells were activated by RXR ligand SR11237 alone (Figure 1b) . Moreover, SR11237 did not enhance the effect of TTNPB on TF expression (Figure 1b) . To confirm the regulation of TF expression by the RAR agonist, we also evaluated the functional properties of expressed TF by measuring procoagulant activity in a two-stage amidolytic assay. 23 RAR ligand TTNPB induced 40% (P Ͻ 0.05) suppression of procoagulant activity, while the activation of RXR had no effect (Figure 1c) . The incomplete suppression of PCA by retinoids in NB4 cells is in agreement with earlier published data, 11, 17, 18 and the residual activity may result from the expression of cancer procoagulant with coagulation factor X activating capacity in NB4 cells. 25 
Activation of RAR␣ in NB4 cells suppresses TF expression
To determine the RAR subtype responsible for TF down-regulation in NB4 cells, we first induced the cells with RAR recep- (Figure 2a) . 26 No changes in TF expression were found after treatment of NB4 cells with the same concentrations of RAR␤ or RAR␥ agonists, Ro48-2249 or Ro44-4753, respectively. Similar to the experiments with the RAR pan-agonist TTNPB (Figure 1) , the activation of the RAR transcriptional partner RXR by SR11237 did not affect TF expression in NB4 APL cells (Figure 2a) . 
Activation of both RAR␣ and RXR are essential for TF suppression in U-937 cells
To investigate if activation of RAR␣ is a general requirement for retinoid-induced TF suppression in myeloid cells, we studied the monoblastic U-937 cell line that constitutively expresses TF. 27 The cells were treated with TTNPB (10
and SR11237 (10 −7 M) as described for NB4 cells. Figure 3 shows that incubation of the U-937 cells with TTNPB or SR11237 alone did not affect the TF mRNA levels, but a slight reduction of TF antigen and TF procoagulant activity was recorded after 48 h. To achieve a complete suppression of TF expression the combination of RAR and RXR agonists was necessary. The combination of TTNPB and SR11237 resulted in TF mRNA, TF antigen and TF PCA down-regulated by 81%, 80% and 78%, respectively (P Ͻ 0.01).
A moderate effect on TF antigen expression by RAR␣ ligand Ro40-6055 was observed in U-937 cells after 48 h ( Figure  4a ). In accordance with results described above the combination of RXR and RAR␣ agonists induced a more pronounced (74%, P Ͻ 0.05) down-regulation of TF. Thus, the activation of the normal RAR␣-RXR transcriptional complex is essential for retinoid induced TF suppression in these cells. To confirm the role of RAR␣ in regulation of TF expression in myeloid cells we blocked RAR␣ activity with Ro41-5253 30 min prior to 48 h ATRA treatment in U-937 cells. There was a concentration-dependent suppression of TF antigen expression by ATRA (Figure 4b ). At the lower ATRA concentrations the RAR␣ antagonist blocked the effect of retinoic acid. The expression of TF was down-regulated by 57% by 10 nM of ATRA, whereas pre-treatment with Ro41-5253 in 1000-fold excess resulted in 16% suppression, being significant at P Ͻ 0.05.
TF and myeloid differentiation markers are inversely regulated
We have earlier suggested that retinoid-induced TF suppression in myeloid cells is accompanied by terminal differentiation. 11 Therefore, we also studied retinoid receptor dependent induction of some myeloid-specific differentiation markers, ie CD11b, CD11c and CD49f (Table 3) . We found pronounced expression of CD11b and CD11c in NB4 APL cells after RAR agonist treatment, while activation of RXR alone had minor effects. The combination of RAR and RXR agonists did not significantly enhance differentiation above RAR activation alone. In contrast, in U-937 cells the activation of RAR-RXR complex was needed for induction of differentiation-related cell-surface receptors (Table 3) .
Discussion
In this study we have shown that the mechanisms of retinoidinduced TF down-regulation in myeloid leukaemic cells are specific for the particular cell type. In the acute promyelocytic leukaemia-derived cell line NB4, the suppression of TF was observed solely after RAR␣ activation, whereas activation of RAR␣ alone was not sufficient for the complete suppression of TF in the monoblastic lymphoma cell line U-937. In these cells the retinoid-induced suppression of TF appeared to be dependent on the activation of both members of RAR␣-RXR transcriptional complex. The successful suppression of TF expression in these two cell lines was found to be consistent with induction of maturation as confirmed by increased expression of myeloid differentiation markers.
Retinoids have been shown to transduce signals leading to cytodifferentiation 28 and concomitant suppression of TF Table 3 The induction of CD11b, CD11c and CD49f expression by SR11237 and TTNPB
CD11b
CD11c CD49f The RAinduced suppression of TF antigen and TF procoagulant activity has been reported to be mediated by activation of RAR␣ and RAR␤ in the APL cell line NB4. 17, 18 However, the reported effect of RAR␤ ligation by Ro48-2249 (10 −8 M) 30 or CD2019 (10 −8 M) 18 was found to be less potent when compared to TF suppression induced by RAR␣ agonist. In our experiments with NB4 and U-937 cell lines we did not observe any effect of the RAR␤ agonist Ro48-2249 on the expression of TF antigen (Figures 2a and 4a) nor on the expression of some general myeloid differentiation markers like CD11b and CD11c (data not shown). The contradictory results concerning the effect of RAR␤-activation on TF regulation might result from some receptor cross-reactivity and different agonist potency of the RAR␤ ligands used in these studies. In NB4 cells the growth inhibition and differentiation are induced with retinoids having only RAR␣ agonist activity. 31, 32 This refers to the specific involvement of RAR␣/PML protein in RA-induced effects in APL cells. However, RAR␤ is expressed in U-937 cells. 33 Although we find it less likely, we cannot completely rule out the possibility of RAR␤ involvement in TF suppression.
Retinoic acid-induced effects are predominantly transduced through activation of RAR-RXR heterodimeric complexes in the RARE of RA-responsive promoter sites. 34 The mechanism by which PML/RAR␣ protein is involved in the leukaemogenesis is not fully understood. In the APL cells, the PML/RAR␣ protein binds to the RARE and associates with the nuclear corepressor proteins like SMRT and N-CoR, 35 and being abundant in these cells might act in a dominant negative manner. Treatment of APL cells with ATRA results in dissociation of SMRT/N-CoR complex and degradation of the PML/RAR␣ protein. 36 Thus, the ligation of PML/RAR␣ by RAR␣ agonist seems to be sufficient to eliminate the leukaemic consequences in NB4 cell line, and so induce the cell differentiation and suppression of TF induction. However, recently a cross-talk between RXR agonists and protein kinase A has been reported also to induce maturation in NB4 cells. 37 This RAR␣-independent pathway seems to be an alternative for the ATRA induced APL differentiation programme, whereas the consequences for TF expression remains to be revealed. Thus, we can not exclude the relevance of RXR in the suppression of TF in APL cells.
RXR has been suggested to act as a silent transcriptional partner to RAR in the heterodimeric complexes. 13 However, several studies have shown that in normal RAR␣ protein expressing myeloid cells the synergistic activation of both partners of the RAR-RXR complex is required for activation of RARE transcriptional activity and for many cellular responses, eg induction of cellular differentiation, growth arrest and retinoblastoma protein phosphorylation. 14, 15, 38 Consistent with these results we show that activation of RAR␣ or RXR alone by synthetic nuclear receptor agonists leads only to a moderate suppression of TF mRNA, TF antigen and TF procoagulant activity in the monoblastic U-937 cells. Full down-regulation was observed when both RAR␣ and RXR were activated. Thus, the suppression of TF seems to require the activation of normal transcriptional complexes, and correlates with other differentiation-associated cellular responses like induction of cell surface antigens (CD11b, CD11c and CD49f).
The suppression of TF in the APL cell line NB4, which possesses the PML/RAR␣ fusion protein, is dependent on the activation of RAR␣ alone. However, in the monoblastic lymphoma cell line U-937 the initiation of processes leading to TF down-regulation are dependent on simultaneous acti-vation of both RAR␣ and RXR. Our observations regarding the distinct mechanisms leading to suppression of the procoagulant properties in different leukaemic cell lines may have implications for the treatment of leukaemia-associated thrombotic complications.
